Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Integra Lifesciences Holdings Q3 2026 Results: Turns Profitable, Net Income $14.9M

Integra LifeSciences reported net income of $14.9 million for the third quarter of 2026, a significant recovery from a net loss of $5.4 million in the prior year period. Total revenue grew slightly to $411.2 million, while the company successfully reduced selling, general, and administrative expenses compared to 2025.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue411.2402.1
Profit before tax15.7-6.8
Net income14.9-5.4
EPS (diluted, $ a share)$0.19$-0.07

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+2.3%
Operating margin4.6%
Source

10-Q filed with the SEC, NASDAQ: IART. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Integra Lifesciences Holdings Corp: key numbers

Share price
$13.55Close, Nov 17
Market cap
$1.05B
Shares outstanding
77.8MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Integra Lifesciences Holdings Corp

All →
6:15 AM ET 8-K
Financial Results

Integra Lifesciences Holdings Financial Results

Integra LifeSciences reported Q3 2026 revenues of $411.2 million, a 2.3% increase year-over-year, despite a $7 million impact from flood damage at its Cincinnati facility. The company achieved GAAP net income of $14.9 million ($0.19 per share) and adjusted EPS of $0.59, while generating $96 million in operating cash flow.

Term
Q3 2026

“Our third quarter performance reflected mixed results across our portfolio, with stronger performance in Specialty Surgery partially offset by a $7 million impact from the Cincinnati disruption and softer-than-expected results in Tissue Reconstruction. We delivered results within our guidance ranges, generated strong cash flow, reduced leverage, and subsequently completed our debt refinancing.”

Stuart Essig, Chairman and Chief Executive Officer

“Our updated outlook reflects both the recovery timeline in Cincinnati and more measured expectations for portions of our Tissue Reconstruction business. We are focused on executing against these challenges while continuing to support our customers, advance key product launches and returns, and strengthen the business for more consistent long-term growth.”

Stuart Essig, Chairman and Chief Executive Officer
4:21 PM ET 8-K
Loan & Debt

Integra Lifesciences Holdings $1.65B Debt Financing with Bank of America, N.A.

Integra LifeSciences completed a comprehensive refinancing of its debt, entering into a new $1.65 billion amended and restated credit agreement and issuing $450 million in 9.500% senior secured notes due 2033. The credit facility includes a $600 million revolver, a $600 million Term Loan A, and a $450 million Term Loan B. Proceeds were used to refinance the company's existing credit facility and pay related fees.

Value
$1.65B
Counterparty
Bank of America, N.A.
Term
5-7 years
5:26 PM ET 8-K
Loan & Debt

Integra Lifesciences Holdings $450M Debt Financing

Integra LifeSciences announced the pricing of $450 million in 9.500% senior secured notes due 2033 in a private placement. The company intends to use the proceeds, along with a new credit facility, to refinance its existing debt obligations. Management noted that this refinancing is expected to increase the company's effective interest rate by approximately 100-200 basis points.

Value
$450M
Term
9 years
8:20 AM ET 8-K
Business Update

Integra Lifesciences Holdings Business Update

Integra LifeSciences announced preliminary Q3 2026 revenue of $410-$412 million and updated its full-year guidance to reflect a $22-$27 million total revenue impact from flooding at its Cincinnati manufacturing facility. The company expects the facility to return to full operations in Q2 2027 and anticipates insurance recoveries to mitigate a substantial portion of the financial impact.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.